Comparative molecular field analysis of selective cyclooxygenase-2 (COX-2) inhibitors

Quantitative Structure-Activity Relationships

Volumn 19, Issue 2, 2000, Pages 127-134

  Marot, Christophe ^a   Chavatte, Philippe ^b   Lesieur, Daniel ^b  

^a UNIVERSITÉ D'ORLÉANS   (France)

^b UNIV LILLE   (France)

Author keywords

CoMFA; COX 2; Cyclooxygenase; NSAIDs; QSAR

Indexed keywords

COMPUTATIONAL CHEMISTRY; MOLECULAR GRAPHICS;

3D-QSAR; COMFA; CYCLO-OXYGENASE-2 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASES; NSAID; QSAR; STERICS; TEST SETS; TRAINING SETS;

ELECTROSTATICS;

5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; CYCLOOXYGENASE 2 INHIBITOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE;

ARTICLE; DRUG BINDING SITE; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 0034010497     PISSN: 09318771     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-3838(200004)19:2<127::AID-QSAR127>3.0.CO;2-P     Document Type: Article

References (23)

1. Reitz, D.B. and Isakson, P.C., Cyclooxygenase-2 inhibitors, Current Pharmaceutical Design 1, 211-220 (1995).
2. Allison, M.C., Howatson, A.G., Torrance, C.J., Lee, F.D. and Russell, R.I.G., Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs, N. Engl. J. Med. 327, 749-754 (1992).
3. Kujubu, D.A., Fletcher, B.S., Varnum, B.C., Lim, R.W. and Herschman, H.R., TIS10, a phorbol ester tumor promoter inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthetase/cyclooxygenase homologue, J. Biol. Chem. 266, 12866-12872 (1991).
4. Lee, S.H., Soyoola, E., Chanmugam, P., Hart, S., Sun, W., Zhong, H., Liou, S., Simmons, D. and Hwang, D., Selective expression of mitogen inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide, J. Biol. Chem. 267, 25934-25938 (1992).
5. O'Sullivan, M.G., Huggins, E.M. and Mccal, C.E., Lipopolysaccharide induced expression of prostaglandin H synthetase 2 in alveolar macrophages is inhibited by dexamethasone but not by aspirin, Biochem. Biophys. Res. Commun. 191, 1294-1300 (1993).
6. Masferrer, J.L., Zweifel, B.S., Manning, P.T., Hauser, S.D., Leahy, K.M., Smith, W.G., Isakson, P.C. and Seibert, K., Selective inhibition of inducible cyclooxygenase-2 in vivo is antiinflammatory and nonulcerogenic, Proc. Natl. Acad. Sci. USA 91, 3228-3232 (1994).
7. Vane, J.R., Mitchell, J.A., Appleton, I., Tomlinson, A., Bishop-Bailey, D., Croxtall, J. and Willoughby, D.A., Inducible isoforms of cyclooxygenase and nitric oxide synthetase in inflammation, Proc. Natl. Acad. Sci. USA 91, 2046-2050 (1994).
8. Harada, Y., Hatanaka, K., Saito, M., Majima, M., Ogino, M., Kawamura, M., Ohno, T., Yang, Q., Katori, M. and Yamamoto, S., Detection of inducible prostaglandin H synthase 2 in cells in the exudate of rat carrageenan induced pleurisy, Biomed. Res. 15, 127-130 (1994).
9. Kennedy, B.P., Chan, C.C., Culp, S.A. and Cromlish, W.A., Cloning and expression of rat prostaglandin endoperoxide synthase cyclooxygenase-2 cDNA, Biochem. Biophys. Res. Commun. 197, 494-500 (1993).
10. Gans, K., Galbraith, W., Roman, R., Haber, S., Kerr, J., Schmidt, W., Smith, C., Hewes, W. and Ackerman, N., Antiinflammatory and safety profile of DuP697, a novel orally prostaglandin synthesis inhibitor, J. Pharm. Exp. Ther. 254, 180-187 (1990).
11. Futaki, N., Yoshikawa, K., Hamasaka, Y., Arai, I., Higuchi, S., Iizuka, H. and Otomo, S., NS398, a novel nonsteroidal antiinflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions, Gen. Pharmacol. 24, 105-110 (1993).
12. Cramer III, R.D., Patterson, D.E. and Bunce J.D., Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins, J. Am. Chem. Soc. 110, 5959-5967 (1988).
13. Li, J.J., Anderson, G.D., Burton, E.G., Cogburn, J.N., Collins, J.T., Garland, D.J., Gregory, S.A., Huang, H.C., Isakson, P.C., Koboldt, C.M., Logusch, E.W., Norton, M.B., Perkins, W.E., Reinhard, E.J., Seibert, K., Veenhuizen, A.W., Zhang, Y. and Reitz, D.B., 1,2-diarylcyclopentenes as selective cyclooxygenase-2 inhibitors and orally active antiinflammatory agents, J. Med. Chem. 38, 4570-4578 (1995).
14. Wilkerson, W.W., Copeland, R.A., Covington, M. and Trzaskos, J.M., Antiinflammatory 4,5-diarylpyrroles. Activity as a function of cyclooxygenase-2 inhibition, J. Med. Chem. 38, 3895-3901 (1995).
15. Li, C.S., Black, W.C., Chan, C.C., Ford-Hutchinson, A.W., Gauthier, J.Y., Gordon, R., Guay, D., Kargman, S., Lau, C.K., Mancini, J., Ouimet, N., Roy, P., Vickers, P., Wong, E., Young, R.N., Zamboni, R. and Prasit, P., Cyclooxygenase-2 inhibitors. Synthesis and pharmacological activities of 5-methanesulfonamido-1-indanone derivatives, J. Med. Chem. 38, 4897-4905 (1995).
16. Reitz, B.B. and Seibert, K., In: Hagmann, P. (Ed.), Selective Cyclooxygenase Inhibitors, Annual Reports in Medicinal Chemistry Chapter 19, Academic Press, 1995, pp. 179-188.
17. Li, J.J., Norton, M.B., Reinhard, E.J., Anderson, G.D., Gregory, S.A., Isakson, P.C., Koboldt, C.M., Masferrer, J.L., Perkins, W.E., Seibert, K., Zhang, Y., Zweifel, B.S. and Reitz, D.B., Novel terphenyls as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents, J. Med. Chem. 39, 1846-1856 (1996).
18. SYBYL 6.2, Tripos Associates, Inc., St. Louis, MO.
19. Clark, M., Cramer III, R.D. and Van Opdenbosch, N., Validation of the General Purpose Tripos 5.2 Force Field, J. Comput. Chem. 10, 982-1012 (1989).
20. Stewart, J.J.P., MOPAC: a semi-empirical molecular orbital program, J. Comput-Aided Mol. Des. 4, 1-103 (1990).
21. Folkers, G., Merz, A. and Rogman, D., CoMFA: scope and limitations. In 3D QSAR in Drug Design. Theory Methods and Applications: Kubinyi, H. (Ed.), ESCOM Science Publishers: Leiden. 1993, pp. 593-618.
22. Clark, M., Cramer III, R.D., The probability of Chance Correlation Using Partial Least Squares (PLS), Quant. Struct.-Act. Relat. 12, 137-145 (1993).
23. Hawkey, C.J., COX-2 inhibitors, The Lancet 353, 309-314 (1999).